Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 19/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 2/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 2/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 2/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.62 |
| ▸ | PRKCG | P05129 | 1/20 | 0.62 |
| ▸ | PRKCB | P05771 | 1/20 | 0.62 |
| ▸ | PRKCA | P17252 | 1/20 | 0.62 |
| ▸ | PRKCH | P24723 | 1/20 | 0.62 |
| ▸ | PRKCI | P41743 | 1/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.62 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264449 | 1.00 | MAP3K8 (1.00) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL29944932 | 1.00 | MAP3K8 (1.00) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5118168 | 0.92 | MAP3K8 (0.85) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5118384 | 0.92 | MAP3K8 (0.85) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4776035 | 0.91 | MAP3K8 (1.00) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL27730160 | 0.90 | MAP3K8 (0.85) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4904414 | 0.90 | MAP3K8 (0.82) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4963305 | 0.90 | MAP3K8 (0.83) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4766912 | 0.89 | MAP3K8 (0.79) | MAP3K8MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4769727 | 0.88 | MAP3K8 (0.79) | MAP3K8MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522872-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-11078540-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-08-03 | — | — | US | claimed |
| US-20150297573-A1 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-10-22 | — | — | US | claimed |
| EP-2911655-A1 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING -CELL SURVIVAL | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-09-02 | — | — | EP | claimed |
| WO-2014064215-A1 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-05-01 | — | — | WO | claimed |
| US-12522872-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250387393-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12370195-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | ACLARIS THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | ACLARIS THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4132524-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | Aclaris Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20210404014-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-20150297573-A1 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-10-22 | — | — | US | disclosed |
| EP-2911655-A1 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING -CELL SURVIVAL | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014064215-A1 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-05-01 | — | — | WO | disclosed |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2545187-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | Dana-Farber Cancer Institute Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112678-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297573-A1 | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL | PNLIP, IAPP, GCKR | MAP3K8 114/4885MAPK13 581/4885MAPK12 916/4885 |
| US-20250387393-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | MAPKAPK2, MAP3K2, MAPK9 | MAP3K8 5/4885MAPK13 30/4885MAPK12 22/4885 |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CNKSR1, DTYMK | MAP3K8 99/4885MAPK13 404/4885MAPK12 778/4885 |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | RPS6KB2, MKNK2, DUSP2 | MAP3K8 12/4885MAPK13 138/4885MAPK12 120/4885 |
| US-20210404014-A1 | METHODS OF DIAGNOSING AND TREATING CANCER IN PATIENTS HAVING OR DEVELOPING RESISTANCE TO A FIRST CANCER THERAPY | CRKL, RAF1, TPX2 | MAP3K8 79/4885MAPK13 695/4885MAPK12 1119/4885 |
| US-11078540-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | CRKL, RAF1, TPX2 | MAP3K8 79/4885MAPK13 695/4885MAPK12 1119/4885 |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | RPS6KB2, MKNK2, DUSP2 | MAP3K8 12/4885MAPK13 138/4885MAPK12 120/4885 |
| US-20130059851-A1 | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy | CRKL, RAF1, TPX2 | MAP3K8 79/4885MAPK13 695/4885MAPK12 1119/4885 |
| US-12370195-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | RPS6KB2, MKNK2, DUSP2 | MAP3K8 12/4885MAPK13 138/4885MAPK12 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.